MedPath

Evaluation of anti-IgE antibody therapy in the patients with wheat allergy

Not Applicable
Conditions
Wheat allergy
Registration Number
JPRN-UMIN000014272
Lead Sponsor
Shimane University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who had been administrated of Omalizumab in history, and patients who receive immunosuppressive drugs.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the sensitization status before and after the therapy using basophil activation test, specific IgE test, and enzyme-linked immunosorbent assay.
Secondary Outcome Measures
NameTimeMethod
Food challenge test before and after the treatment if available.
© Copyright 2025. All Rights Reserved by MedPath